• Syntis Bio: Solutions to Unlock Obesity and Metabolic Disorders

  • Apr 25 2024
  • Duración: 27 m
  • Podcast

Syntis Bio: Solutions to Unlock Obesity and Metabolic Disorders

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • In this episode of Just Bold Enough, Teymour and Felicia discuss an innovative biotech company, Syntis Bio, and how it will disrupt obesity treatment. Syntis has developed a gastric bypass-in-a-pill that blocks the absorption of glucose in the small intestine. This simple, yet clever solution could revolutionize the treatment of obesity and have a significant impact on the pharmaceutical industry by improving the delivery of other drugs. The team is led by experienced CEO, Rahul Dhanda, who is now leading the company into human clinical trials. The company also prioritizes health equity by aiming to disrupt the high cost of obesity treatments such as Ozempic and make it more accessible to those who need it.

    Story Notes:

    • Addressing the Obesity Challenge
    • Navigating the Regulatory Landscape
    • The Potential Impact on the Pharmaceutical Industry

    To learn more, visit:
    https://boldcapitalpartners.com/
    Más Menos
Más Menos
activate_Holiday_promo_in_buybox_DT_T2

Lo que los oyentes dicen sobre Syntis Bio: Solutions to Unlock Obesity and Metabolic Disorders

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles